November 10, 2015
CA 19-9 tumor marker test especially important for early-stage patients, Mayo finds Only 1 in 5 U.S. pancreatic cancer patients receive a widely available, inexpensive blood test at diagnosis that can help predict whether they are likely to have a better or worse outcome than average and guide treatment accordingly, a Mayo Clinic study shows. […]
Tags: Carlos Puig, Center for the Science of Health Care Delivery, Christopher Shubert, David Nagorney, Elizabeth Habermann, John (Jay) Bergquist, Mark Truty, Michael Farnell, Michael Kendrick, pancreatic cancer, Rory Smoot, Ryan Groeschl